Neurosurgeon Alan Chiang, MD, has joined the board of directors for clinical-stage medical biotechnology company NeOnc Technologies Holdings.
Dr. Chiang has expertise in minimally invasive spine surgery, brain tumor treatment and biotechnology innovation, according to a March 25 news release.
NeOnc is currently focused on the research and development of central nervous system therapeutics, including chemotherapy agents NEO100 and NEO212, which are currently undergoing human clinical trials.
Dr. Chiang is a neurosurgeon and associate professor of neurosurgery at Fu Jen Catholic University Hospital in New Taipei City, Taiwan. He also founded biotechnology companies Neucen Biomedical and Orion Biotech.
